Skip to main content
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ARMP ISIN · US04216R1023 LEI · 549300QM1VCWH8KT0S21 US Manufacturing
Open in API
Filings indexed 1,011 across all filing types
Latest filing 2005-11-30 Regulatory Filings
Country US United States of America
Listing US ARMP

About Armata Pharmaceuticals, Inc.

https://www.armatapharma.com/

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat the global threat of antibiotic-resistant infections. The company's core focus is on creating precisely targeted, high-purity phage-based treatments for serious bacterial infections. This approach aims to provide an effective alternative to conventional antibiotics by eliminating harmful bacteria while preserving the patient's healthy microbiome. Armata's pipeline includes product candidates targeting multi-drug resistant pathogens, supported by its in-house cGMP manufacturing facility for clinical and commercial supply.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes an announcement of a contract award related to vaccine development, referencing a press release attached as an exhibit. There are no financial statements or detailed financial data presented, and the document is relatively short (2755 characters). It is not an annual or quarterly report, nor an earnings release, nor a management discussion. The document is primarily an announcement of a significant event (contract award) and includes a press release. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2005-11-30 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated November 14, 2005. It announces the start of a Phase II clinical trial for an HIV vaccine candidate and includes a press release as an exhibit. The document is relatively short (2674 characters) and primarily serves as an announcement of an event rather than a detailed financial report or other specific filing type. It does not contain financial statements, management discussion, or detailed financial data. The presence of a press release as an exhibit and the nature of the content indicate this is a Regulatory Filing (RNS) as it does not fit into more specific categories like Earnings Release or Management Reports. Therefore, the appropriate classification is Regulatory Filings (RNS).
2005-11-15 English
FORM 10-Q
Interim / Quarterly Report Q3 2005
2005-11-03 English
FORM 4 SUBMISSION
Director's Dealing
2005-11-02 English
FORM 3 SUBMISSION
Director's Dealing
2005-11-02 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated October 31, 2005. It reports the appointment of a new director and provides information about clinical trial data announcements. The document includes press releases as exhibits. The content focuses on management changes and other corporate events rather than financial results or detailed reports. The key section is Item 5.02, which is about the departure and appointment of directors or principal officers, indicating a change in senior management. Therefore, this filing is best classified as Board/Management Information (MANG). The document length is 4345 characters, which is consistent with a typical 8-K report on management changes rather than a full annual or quarterly report.
2005-11-02 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.